Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 12/2023

03-11-2023 | Glioma | Review

Advances in Treatment of Diffuse Midline Gliomas

Authors: Chantel Cacciotti, Karen D. Wright

Published in: Current Neurology and Neuroscience Reports | Issue 12/2023

Login to get access

Abstract

Purpose of Review

Diffuse midline gliomas (DMGs) generally carry a poor prognosis, occur during childhood, and involve midline structures of the central nervous system, including the thalamus, pons, and spinal cord.

Recent Findings

To date, irradiation has been shown to be the only beneficial treatment for DMG. Various genetic modifications have been shown to play a role in the pathogenesis of this disease. Current treatment strategies span targeting epigenetic dysregulation, cell cycle, specific genetic alterations, and the immune microenvironment.

Summary

Herein, we review the complex features of this disease as it relates to current and past therapeutic approaches.
Literature
1.
2.
Buczkowicz P, Bartels U, Bouffet E, Becher O, Hawkins C. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol. 2014;128(4):573–81.PubMedPubMedCentralCrossRef
3.
Cohen KJ, Jabado N, Grill J. Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope? Neuro Oncol. 2017;19(8):1025–34.PubMedPubMedCentralCrossRef
4.
Karremann M, Gielen GH, Hoffmann M, Wiese M, Colditz N, Warmuth-Metz M, et al. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro Oncol. 2018;20(1):123–31.PubMedCrossRef
5.
Vitanza NA, Cho YJ. Advances in the biology and treatment of pediatric central nervous system tumors. Curr Opin Pediatr. 2016;28(1):34–9.PubMedCrossRef
6.
Caretti V, Bugiani M, Freret M, Schellen P, Jansen M, van Vuurden D, et al. Subventricular spread of diffuse intrinsic pontine glioma. Acta Neuropathol. 2014;128(4):605–7.PubMedPubMedCentralCrossRef
7.
Benesch M, Wagner S, Berthold F, Wolff JE. Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH). J Neurooncol. 2005;72(2):179–83.PubMedCrossRef
8.
Wagner S, Benesch M, Berthold F, Gnekow AK, Rutkowski S, Sträter R, et al. Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas. Br J Cancer. 2006;95(8):991–7.PubMedPubMedCentralCrossRef
9.
Vallero SG, Bertero L, Morana G, Sciortino P, Bertin D, Mussano A, et al. Pediatric diffuse midline glioma H3K27- altered: a complex clinical and biological landscape behind a neatly defined tumor type. Front Oncol. 2022;12:1082062.PubMedCrossRef
10.
Mondal G, Lee JC, Ravindranathan A, Villanueva-Meyer JE, Tran QT, Allen SJ, et al. Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition. Acta Neuropathol. 2020;139(6):1071–88.PubMedPubMedCentralCrossRef
11.
Sievers P, Sill M, Schrimpf D, Stichel D, Reuss DE, Sturm D, et al. A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. Neuro Oncol. 2021;23(1):34–43.PubMedCrossRef
12.
13.
Puget S, Philippe C, Bax DA, Job B, Varlet P, Junier MP, et al. Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PloS One. 2012;7(2):e30313.PubMedPubMedCentralCrossRef
14.
Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol. 2011;29(30):3999–4006.PubMedPubMedCentralCrossRef
15.
Edwards M, Wara W, Urtasun R, Prados M, Levin V, Fulton D, et al. Hyperfractionated radiation therapy for brain-stem glioma: a phase I-II trial. J Neurosurg. 1989;70:691–700.PubMedCrossRef
16.
Freeman C, Krischer J, Sanford R, Cohen M, Burger P, Del Carpio R, et al. Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys. 1993;27:197–206.PubMedCrossRef
17.
Packer R, Boyett J, Zimmerman R, Rorke L, Kaplan A, Albright A, et al. Hyperfractionated radiation therapy (72 Gy) for children with brain stem glioma: a Children’s Cancer Group Phase I/II Trial. Cancer. 1993;72:1414–21.PubMedCrossRef
18.
Veldhuijzen van Zanten SEM, El-Khouly FE, Jansen MHA, Bakker DP, Sanchez Aliaga E, Haasbeek CJA, et al. A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol. 2017;135(2):307–15.PubMedPubMedCentralCrossRef
19.
20.
Chornenkyy Y, Agnihotri S, Yu M, Buczkowicz P, Rakopoulos P, Golbourn B, et al. Poly-ADP-ribose polymerase as a therapeutic target in pediatric diffuse intrinsic pontine glioma and pediatric high-grade astrocytoma. Mol Cancer Ther. 2015;14(11):2560–8.PubMedCrossRef
21.
Lesueur P, Chevalier F, Austry JB, Waissi W, Burckel H, Noël G, et al. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget. 2017;8(40):69105–24.PubMedPubMedCentralCrossRef
22.
van Vuurden DG, Hulleman E, Meijer OL, Wedekind LE, Kool M, Witt H, et al. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget. 2011;2(12):984–96.PubMedPubMedCentralCrossRef
23.
Amsbaugh MJ, Mahajan A, Thall PF, McAleer MF, Paulino AC, Grosshans D, et al. A phase 1/2 trial of reirradiation for diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2019;104(1):144–8.PubMedCrossRef
24.
Fontanilla HP, Pinnix CC, Ketonen LM, Woo SY, Vats TS, Rytting ME, et al. Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol. 2012;35(1):51–7.PubMedCrossRef
25.
Lassaletta A, Strother D, Laperriere N, Hukin J, Vanan MI, Goddard K, et al. Reirradiation in patients with diffuse intrinsic pontine gliomas: the Canadian experience. Pediatr Blood Cancer. 2018;65(6):e26988.PubMedCrossRef
26.
Cacciotti C, Liu KX, Haas-Kogan DA, Warren KE. Reirradiation practices for children with diffuse intrinsic pontine glioma. Neurooncol Pract. 2021;8(1):68–74.PubMed
27.
Fontanilla H, Pinnix C, Ketonen L, et al. Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol. 2012;35(1):51–7.PubMedCrossRef
28.
Massimino M, Biassoni V, Miceli R et al. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J Neurooncol. 2014;118(2):305–12.PubMed
29.
Janssens G, Gandola L, Bolle S et al. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Eur J Cancer. 2017;73:38–47.PubMedCrossRef
30.
Amsbaugh M, Mahajan A, Thall P et al. A phase 1/2 trial of reirradiation for diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2019;104(1):144–8.PubMedCrossRef
31.
Rodriguez D, Calmon R, Aliaga ES, Warren D, Warmuth-Metz M, Jones C, et al. MRI and molecular characterization of pediatric high-grade midline thalamic gliomas: the HERBY Phase II Trial. Radiology. 2022;304(1):174–82.PubMedCrossRef
32.
Jansen MH, van Vuurden DG, Vandertop WP, Kaspers GJ. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev. 2012;38(1):27–35.PubMedCrossRef
33.
Sanghavi SN, Needle MN, Krailo MD, Geyer JR, Ater J, Mehta MP. A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children’s Cancer Group-0952. Neuro Oncol. 2003;5(1):8–13.PubMedPubMedCentralCrossRef
34.
Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol. 2011;13(4):410–6.PubMedPubMedCentralCrossRef
35.
Wagner S, Reinert C, Schmid HJ, Liebeskind AK, Jorch N, Längler A, et al. High-dose methotrexate prior to simultaneous radiochemotherapy in children with malignant high-grade gliomas. Anticancer Res. 2005;25(3c):2583–7.PubMed
36.
Itazaki H, Nagashima K, Sugita K, Yoshida H, Kawamura Y, Yasuda Y, et al. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J Antibiot (Tokyo). 1990;43(12):1524–32.PubMedCrossRef
37.
Sugita K, Koizumi K, Yoshida H. Morphological reversion of sis-transformed NIH3T3 cells by trichostatin A. Cancer Res. 1992;52(1):168–72.PubMed
38.
Medina V, Edmonds B, Young G, James R, Appleton S, Zalewski P. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res. 1997;57(17):3697–707.PubMed
39.
Leszczynska KB, Jayaprakash C, Kaminska B, Mieczkowski J. Emerging advances in combinatorial treatments of epigenetically altered pediatric high-grade H3K27M gliomas. Front Genet. 2021;12:742561.PubMedPubMedCentralCrossRef
40.
Hennika T, Hu G, Olaciregui NG, Barton KL, Ehteda A, Chitranjan A, et al. Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models. PloS One. 2017;12(1):e0169485.PubMedPubMedCentralCrossRef
41.
Wang ZJ, Ge Y, Altinok D, Poulik J, Sood S, Taub JW, et al. Concomitant use of panobinostat and reirradiation in progressive DIPG: report of 2 cases. J Pediatr Hematol Oncol. 2017;39(6):e332–e5.PubMedCrossRef
42.
Su JM, Kilburn LB, Mansur DB, Krailo M, Buxton A, Adekunle A, et al. Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: a Children’s Oncology Group report. Neuro Oncol. 2022;24(4):655–64.PubMedCrossRef
43.
Truffaux N, Philippe C, Paulsson J, Andreiuolo F, Guerrini-Rousseau L, Cornilleau G, et al. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma. Neuro Oncol. 2015;17(7):953–64.PubMedCrossRef
44.
Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, Phillips P, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007;9(2):145–60.PubMedPubMedCentralCrossRef
45.
Broniscer A, Baker SD, Wetmore C, Pai Panandiker AS, Huang J, Davidoff AM, et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin Cancer Res. 2013;19(11):3050–8.PubMedPubMedCentralCrossRef
46.
Broniscer A, Baker JN, Tagen M, Onar-Thomas A, Gilbertson RJ, Davidoff AM, et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol. 2010;28(31):4762–8.PubMedPubMedCentralCrossRef
47.
Carvalho DM, Richardson PJ, Olaciregui N, Stankunaite R, Lavarino C, Molinari V, et al. Repurposing vandetanib plus everolimus for the treatment of. Cancer Discov. 2022;12(2):416–31.PubMedCrossRef
48.
Geyer JR, Stewart CF, Kocak M, Broniscer A, Phillips P, Douglas JG, et al. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer. 2010;46(18):3287–93.PubMedPubMedCentralCrossRef
49.
Geoerger B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, Andreiuolo F, et al. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol. 2011;13(1):109–18.PubMedCrossRef
50.
Grill J, Le Teuff G, Nysom K, Blomgren K, Hargrave D, McCowage G, et al. PDCT-01. Biological medicine for diffuse intrinsic pontine gliomas eradication (Biomede): results of the three-arm biomarker-driveN randomized trial in the first 230 patients from Europe and Australia. Neuro Oncol. 2019;21:vi183. © The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.comPubMedCentralCrossRef
51.
Persson ML, Douglas AM, Alvaro F, Faridi P, Larsen MR, Alonso MM, et al. The intrinsic and microenvironmental features of diffuse midline glioma: implications for the development of effective immunotherapeutic treatment strategies. Neuro Oncol. 2022;24(9):1408–22.PubMedPubMedCentralCrossRef
52.
Becher OJ, Millard NE, Modak S, Kushner BH, Haque S, Spasojevic I, et al. A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. PloS One. 2017;12(6):e0178593.PubMedPubMedCentralCrossRef
53.
54.
Erker C, Lane A, Chaney B, Leary S, Minturn JE, Bartels U, et al. Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro Oncol. 2022;24(1):141–52.PubMedCrossRef
55.
56.
Massimino M, Biassoni V, Miceli R, Schiavello E, Warmuth-Metz M, Modena P, et al. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J Neurooncol. 2014;118(2):305–12.PubMed
57.
Fleischhack G, Massimino M, Warmuth-Metz M, Khuhlaeva E, Janssen G, Graf N, et al. Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study. J Neurooncol. 2019;143(1):107–13.PubMedCrossRef
58.
Kebudi R, Cakir FB, Bay SB, Gorgun O, Altınok P, Iribas A, et al. Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature. Childs Nerv Syst. 2019;35(1):83–9.PubMedCrossRef
59.
Parenrengi MA, Suryaningtyas W, Al Fauzi A, Hafid Bajamal A, Kusumastuti K, Utomo B, et al. Nimotuzumab as additional therapy for GLIOMA in pediatric and adolescent: a systematic review. Cancer Control. 2022;29:10732748211053927.PubMedPubMedCentralCrossRef
60.
Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23(1):74–88.PubMedCrossRef
61.
DeWire M, Fuller C, Hummel TR, Chow LML, Salloum R, de Blank P, et al. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). J Neurooncol. 2020;149(3):511–22.PubMedCrossRef
62.
Schüller U, Iglauer P, Dorostkar MM, Mawrin C, Herms J, Giese A, et al. Mutations within FGFR1 are associated with superior outcome in a series of 83 diffuse midline gliomas with H3F3A K27M mutations. Acta Neuropathol. 2021;141(2):323–5.PubMedPubMedCentralCrossRef
63.
Nguyen AT, Colin C, Nanni-Metellus I, Padovani L, Maurage CA, Varlet P, et al. Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours. Neuropathol Appl Neurobiol. 2015;41(3):403–8.PubMedCrossRef
64.
Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJ, et al. Diffuse midline gliomas with histone H3-K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol. 2016;26(5):569–80.PubMedCrossRef
65.
Joyon N, Tauziède-Espariat A, Alentorn A, Giry M, Castel D, Capelle L, et al. K27M mutation in H3F3A in ganglioglioma grade I with spontaneous malignant transformation extends the histopathological spectrum of the histone H3 oncogenic pathway. Neuropathol Appl Neurobiol. 2017;43(3):271–6.PubMedCrossRef
66.
Pagès M, Beccaria K, Boddaert N, Saffroy R, Besnard A, Castel D, et al. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma. Brain Pathol. 2018;28(1):103–11.PubMedCrossRef
67.
Ryall S, Zapotocky M, Fukuoka K, Nobre L, Guerreiro Stucklin A, Bennett J, et al. Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell. 2020;37(4):569–83.e5.PubMedPubMedCentralCrossRef
68.
Blumenthal DT, Yalon M, Vainer GW, Lossos A, Yust S, Tzach L, et al. Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. J Neurooncol. 2016;129(3):453–60.PubMedCrossRef
69.
Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25(3):477–86.PubMedPubMedCentralCrossRef
70.
71.
Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123(11):1904–11.PubMedCrossRef
72.
Cacciotti C, Choi J, Alexandrescu S, Zimmerman MA, Cooney TM, Chordas C, et al. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience. J Neurooncol. 2020;149(1):113–22.PubMedCrossRef
73.
Kline C, Liu SJ, Duriseti S, Banerjee A, Nicolaides T, Raber S, et al. Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. J Neurooncol. 2018;140(3):629–38.PubMedCrossRef
74.
Hwang E, Onar A, Young-Poussaint T, Mitchell D, Kilburn L, Margol A, et al. IMMU-09.Outcome of patients with recurrent diffuse intrinsic pontine glioma (DIPG) treated with pembrolizumab (anti-PD-1): a pediatric brain tumor consortium study (PBTC045). Neuro Oncol. 2018;20(Suppl 2):i100.PubMedCentralCrossRef
75.
Ochs K, Ott M, Bunse T, Sahm F, Bunse L, Deumelandt K, et al. K27M-mutant histone-3 as a novel target for glioma immunotherapy. Oncoimmunology. 2017;6(7):e1328340.PubMedPubMedCentralCrossRef
76.
Vandenberk L, Belmans J, Van Woensel M, Riva M, Van Gool SW. Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines. Front Immunol. 2015;6:663.PubMed
77.
Benitez-Ribas D, Cabezón R, Flórez-Grau G, Molero MC, Puerta P, Guillen A, et al. Immune response generated with the administration of autologous dendritic cells pulsed with an allogenic tumoral cell-lines lysate in patients with newly diagnosed diffuse intrinsic pontine glioma. Front Oncol. 2018;8:127.PubMedPubMedCentralCrossRef
78.
Martínez-Vélez N, Garcia-Moure M, Marigil M, González-Huarriz M, Puigdelloses M, Gallego Pérez-Larraya J, et al. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat Commun. 2019;10(1):2235.PubMedPubMedCentralCrossRef
79.
de Billy E, Pellegrino M, Orlando D, Pericoli G, Ferretti R, Businaro P, et al. Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant. Neuro Oncol. 2022;24(7):1150–63.PubMedCrossRef
80.
Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022;603(7903):934–41.PubMedPubMedCentralCrossRef
81.
Mount CW, Majzner R, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, et al. Abstract 958: Anti-GD2 chimeric antigen receptor T cells as a potent immunotherapy regimen in xenograft models of histone 3 K27M mutant diffuse midline glioma. Cancer Res. 2018;78(13 Supplement):958.CrossRef
82.
Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat Med. 2018;24(5):572.PubMedPubMedCentralCrossRef
Metadata
Title
Advances in Treatment of Diffuse Midline Gliomas
Authors
Chantel Cacciotti
Karen D. Wright
Publication date
03-11-2023
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 12/2023
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-023-01317-8

Other articles of this Issue 12/2023

Current Neurology and Neuroscience Reports 12/2023 Go to the issue

Review

Neural Control of REM Sleep and Motor Atonia: Current Perspectives

Review

Recent Developments in Blood Biomarkers in Neuro-oncology

Review

Autonomic Manifestations of Long-COVID Syndrome

Review

Revisiting Functional Dysconnectivity: a Review of Three Model Frameworks in Schizophrenia

Review

Neuromodulation for Post-Stroke Motor Recovery: a Narrative Review of Invasive of Invasive and Non‑Invasive Tools

Review

Disparities in Neuro-Oncology